Rafferty Asset Management LLC cut its position in Gossamer Bio, Inc. (NASDAQ:GOSS) by 35.0% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 112,850 shares of the company’s stock after selling 60,778 shares during the quarter. Rafferty Asset Management LLC owned about 0.15% of Gossamer Bio worth $916,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Nisa Investment Advisors LLC bought a new stake in Gossamer Bio in the 2nd quarter valued at $339,000. Rhumbline Advisers boosted its stake in Gossamer Bio by 11.6% in the 2nd quarter. Rhumbline Advisers now owns 87,324 shares of the company’s stock valued at $709,000 after purchasing an additional 9,056 shares during the period. Texas Yale Capital Corp. bought a new stake in Gossamer Bio in the 2nd quarter valued at $81,000. Advisor Group Holdings Inc. boosted its stake in Gossamer Bio by 193.1% in the 2nd quarter. Advisor Group Holdings Inc. now owns 3,567 shares of the company’s stock valued at $29,000 after purchasing an additional 2,350 shares during the period. Finally, Emerald Mutual Fund Advisers Trust boosted its stake in Gossamer Bio by 181.3% in the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 1,261,080 shares of the company’s stock valued at $10,240,000 after purchasing an additional 812,728 shares during the period. Institutional investors and hedge funds own 69.03% of the company’s stock.
Gossamer Bio stock opened at $11.34 on Wednesday. The company has a debt-to-equity ratio of 0.80, a quick ratio of 13.91 and a current ratio of 13.91. Gossamer Bio, Inc. has a 52 week low of $7.04 and a 52 week high of $13.65. The stock has a market capitalization of $861.77 million, a P/E ratio of -3.48 and a beta of 1.27. The stock has a fifty day moving average of $8.93 and a 200-day moving average of $8.84.
Several research firms recently issued reports on GOSS. Piper Sandler began coverage on Gossamer Bio in a research note on Monday. They issued a “buy” rating and a $26.00 price target for the company. Zacks Investment Research downgraded Gossamer Bio from a “hold” rating to a “sell” rating in a research report on Thursday, August 12th. Finally, SVB Leerink cut their target price on Gossamer Bio from $19.00 to $15.00 and set an “outperform” rating for the company in a research report on Tuesday, August 10th. One equities research analyst has rated the stock with a sell rating and six have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Buy” and an average target price of $19.86.
About Gossamer Bio
Gossamer Bio, Inc engages in discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. Its primary product candidate, GB001, is intended for the treatment of moderate-to-severe eosinophilic asthma and other allergic conditions.
Read More: Why is cost of goods sold important?
Receive News & Ratings for Gossamer Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gossamer Bio and related companies with MarketBeat.com's FREE daily email newsletter.